I have heard well informed people say that they think, in terms of carcinogenicity, the napthalene moiety is a red herring, but why? If napthalene is not to blame then what is? Regardless, when one exchanges a 2-methoxyphenyl for napthalene the decrease in potency and binding at CB1 is modest enough that there is really no reason to continue using and selling these naphthyl compounds. In terms of subjective effects the N-butyl compounds like JWH-073 are superior to the more potent N-pentyls - so what about N-butyl JWH-250? I'm sure Huffman has synthed it but I can't look up its numerical designation right now, what I do know is that it has never been sold. It would be only a hair less potent than JWH-073, the same goes for the WIN55212-x compounds which are unexplored and fertile territory and as far as I can tell have never undergone 3-methoxyphenyl substitution.
I wish there were more work done to elucidate the nuanced effects of these cannabinoids - sure affinity at CB1 is an important measure of potency but why are certain cannabinoids more colorful - or psychedelic - or stimulating? As technology stands such tests would require human consumption and a cannabinoid version of Pihkal would probably be very (very) redundant. But now that im getting really into the SAR of CB1 agonists I'm realizing what an insane ligand whore that receptor really is - there is no hope in creating tests to screen for them all - this is only the beginning!!!
Ah, so much work to be done...